Meredith M. Regan, ScD
Meredith M. Regan, ScD
Dana-Farber Cancer Institute, Harvard Medical School
Verified email at
Cited by
Cited by
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk
HK Meier-Ewert, PM Ridker, N Rifai, MM Regan, NJ Price, DF Dinges, ...
Journal of the American College of Cardiology 43 (4), 678-683, 2004
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ...
The lancet oncology 14 (4), 297-305, 2013
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
Q Wang, W Li, Y Zhang, X Yuan, K Xu, J Yu, Z Chen, R Beroukhim, ...
Cell 138 (2), 245-256, 2009
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott, MM Regan, JI Clark, LE Flaherty, GR Weiss, TF Logan, ...
Journal of clinical oncology 23 (1), 133-141, 2005
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.
KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ...
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ...
New England Journal of Medicine 371 (2), 107-118, 2014
Adjuvant ovarian suppression in premenopausal breast cancer
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...
New England Journal of Medicine 372 (5), 436-446, 2015
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
MM Pomerantz, N Ahmadiyeh, L Jia, P Herman, MP Verzi, ...
Nature genetics 41 (8), 882-884, 2009
Tailoring adjuvant endocrine therapy for premenopausal breast cancer
PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ...
New England Journal of Medicine 379 (2), 122-137, 2018
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, ...
Annals of Oncology 30 (10), 1541-1557, 2019
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey, JR Crews, N Denduluri, ES Hwang, ...
Journal of Clinical Oncology 39 (13), 1485, 2021
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy …
G Viale, MM Regan, E Maiorano, MG Mastropasqua, P Dell'Orto, ...
Journal of Clinical Oncology 25 (25), 3846-3852, 2007
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
M Atkins, M Regan, D McDermott, J Mier, E Stanbridge, A Youmans, ...
Clinical cancer research 11 (10), 3714-3721, 2005
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ...
Annals of oncology 32 (10), 1216-1235, 2021
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
The system can't perform the operation now. Try again later.
Articles 1–20